BioCentury | Jan 11, 2016
Company News

KineMed, Pfizer deal

...The companies partnered to use KineMed’s kinetic biomarker technology to discover and develop biomarkers. The companies...
...will target cardiovascular, metabolic and neurology areas. Pfizer said it has not selected targets yet. KineMed...
...receive an upfront payment and R&D funding and is eligible for development and regulatory milestones. KineMed’s...
BioCentury | Oct 12, 2015
Company News

BioPharma Forest, KineMed deal

...Biopharma Forest granted KineMed exclusive, worldwide rights, except Japan, Korea, Taiwan and China, to develop and...
...and China, to develop and commercialize synthetic ghrelin for all indications except amyotrophic lateral sclerosis. KineMed...
...receive milestones, plus royalties. The company plans to start a Phase II trial next year. KineMed...
BioCentury | Jun 29, 2015
Company News

KineMed, Pronutria deal

...The companies partnered to use KineMed’s proteomics technology to evaluate the physiological effects of Pronutria’s biologics...
...effects of Pronutria’s biologics that restore cellular hemostasis. The companies did not disclose financial details. KineMed Inc....
BioCentury | Jul 28, 2014
Financial News

KineMed withdraws IPO

...& Co. Ltd. Note: KineMed withdrew its IPO on NASDAQ, citing “market conditions.” Last month, KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...
BioCentury | Jul 24, 2014
Financial News

KineMed pulls IPO

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) withdrew its IPO on NASDAQ, citing "market conditions." The company...
...NASDAQ, citing "market conditions." The company declined to comment on future financing plans. Last month, KineMed...
...operating loss of $1.7 million. As of March 31, KineMed had $7.3 million in cash. KineMed...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...Catalent Inc. (NYSE) 1/24/14 Up to $100M Mkt (services) Microlin Bio Inc. 1/10/14 $30M Preclin KineMed Inc....
BioCentury | Jun 16, 2014
Company News

KineMed, Pfizer deal

...The companies again extended a 2012 non-exclusive research deal to use KineMed's Dynamic Proteomics technology to...
...and KineMed could not be reached (see BioCentury, Feb. 6, 2012 & April 1, 2013). KineMed Inc....
BioCentury | Jun 16, 2014
Financial News

KineMed amends IPO

...to $33.8 million Shares: 4.5 million Price: $6.50-$7.50 Underwriter: Feltl; MLV; Laidlaw Overallotment: 675,000 Note: KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...
BioCentury | Jun 10, 2014
Financial News

KineMed sets IPO range

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) amended its IPO on NASDAQ and now plans to sell...
...million and be valued at $113.8 million. Feltl and Co.; MLV; and Laidlaw are underwriters. KineMed...
...NYSE:PFE) and AstraZeneca plc (LSE:AZN; NYSE:AZN), as well as collaborations with not-for-profits and government agencies. KineMed...
BioCentury | May 26, 2014
Company News

KineMed management update

KineMed Inc. , Emeryville, Calif. Business: Musculoskeletal, Neurology, Cardiovascular Hired: Patrick James Doyle as EVP and CBO, formerly VP of strategic partnerships at PPD LLC WIR Staff Cardiovascular Musculoskeletal Neurology...
Items per page:
1 - 10 of 59
BioCentury | Jan 11, 2016
Company News

KineMed, Pfizer deal

...The companies partnered to use KineMed’s kinetic biomarker technology to discover and develop biomarkers. The companies...
...will target cardiovascular, metabolic and neurology areas. Pfizer said it has not selected targets yet. KineMed...
...receive an upfront payment and R&D funding and is eligible for development and regulatory milestones. KineMed’s...
BioCentury | Oct 12, 2015
Company News

BioPharma Forest, KineMed deal

...Biopharma Forest granted KineMed exclusive, worldwide rights, except Japan, Korea, Taiwan and China, to develop and...
...and China, to develop and commercialize synthetic ghrelin for all indications except amyotrophic lateral sclerosis. KineMed...
...receive milestones, plus royalties. The company plans to start a Phase II trial next year. KineMed...
BioCentury | Jun 29, 2015
Company News

KineMed, Pronutria deal

...The companies partnered to use KineMed’s proteomics technology to evaluate the physiological effects of Pronutria’s biologics...
...effects of Pronutria’s biologics that restore cellular hemostasis. The companies did not disclose financial details. KineMed Inc....
BioCentury | Jul 28, 2014
Financial News

KineMed withdraws IPO

...& Co. Ltd. Note: KineMed withdrew its IPO on NASDAQ, citing “market conditions.” Last month, KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...
BioCentury | Jul 24, 2014
Financial News

KineMed pulls IPO

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) withdrew its IPO on NASDAQ, citing "market conditions." The company...
...NASDAQ, citing "market conditions." The company declined to comment on future financing plans. Last month, KineMed...
...operating loss of $1.7 million. As of March 31, KineMed had $7.3 million in cash. KineMed...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...Catalent Inc. (NYSE) 1/24/14 Up to $100M Mkt (services) Microlin Bio Inc. 1/10/14 $30M Preclin KineMed Inc....
BioCentury | Jun 16, 2014
Company News

KineMed, Pfizer deal

...The companies again extended a 2012 non-exclusive research deal to use KineMed's Dynamic Proteomics technology to...
...and KineMed could not be reached (see BioCentury, Feb. 6, 2012 & April 1, 2013). KineMed Inc....
BioCentury | Jun 16, 2014
Financial News

KineMed amends IPO

...to $33.8 million Shares: 4.5 million Price: $6.50-$7.50 Underwriter: Feltl; MLV; Laidlaw Overallotment: 675,000 Note: KineMed...
...up to $50.9 million, with H.C. Wainwright; MKM Dillon; and Dawson James Securities as underwriters. KineMed...
BioCentury | Jun 10, 2014
Financial News

KineMed sets IPO range

...Biomarker discovery company KineMed Inc. (Emeryville, Calif.) amended its IPO on NASDAQ and now plans to sell...
...million and be valued at $113.8 million. Feltl and Co.; MLV; and Laidlaw are underwriters. KineMed...
...NYSE:PFE) and AstraZeneca plc (LSE:AZN; NYSE:AZN), as well as collaborations with not-for-profits and government agencies. KineMed...
BioCentury | May 26, 2014
Company News

KineMed management update

KineMed Inc. , Emeryville, Calif. Business: Musculoskeletal, Neurology, Cardiovascular Hired: Patrick James Doyle as EVP and CBO, formerly VP of strategic partnerships at PPD LLC WIR Staff Cardiovascular Musculoskeletal Neurology...
Items per page:
1 - 10 of 59